Drug Type Small molecule drug |
Synonyms ADC-3680, ADC-3680B, ADC3680 + [5] |
Target |
Action antagonists |
Mechanism CRTH2 antagonists(Prostaglandin D2 receptor 2 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC21H17Cl2F2NO4 |
InChIKeyLZLJEKKWOIJMSR-UHFFFAOYSA-N |
CAS Registry932708-14-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Chronic rhinosinusitis with nasal polyps | Phase 2 | United States | 16 May 2019 | |
Chronic rhinosinusitis with nasal polyps | Phase 2 | Czechia | 16 May 2019 | |
Chronic rhinosinusitis with nasal polyps | Phase 2 | Ukraine | 16 May 2019 | |
Nasal Polyps | Phase 2 | United States | 16 May 2019 | |
Nasal Polyps | Phase 2 | Czechia | 16 May 2019 | |
Nasal Polyps | Phase 2 | Ukraine | 16 May 2019 | |
Asthma | Phase 2 | United States | 01 Apr 2013 | |
Asthma | Phase 2 | Croatia | 01 Apr 2013 | |
Asthma | Phase 2 | Czechia | 01 Apr 2013 | |
Asthma | Phase 2 | Germany | 01 Apr 2013 |
Phase 2 | 481 | Placebo (Placebo) | ownftimalt = jytbzkpemq vhfcwfrpes (nbtrupxdbi, wfbdfwcxbd - xrmndtlquf) View more | - | 23 Aug 2021 | ||
(GB001 20 mg) | ownftimalt = beivogiwxz vhfcwfrpes (nbtrupxdbi, vdxytazcyy - qffqmauaiu) View more | ||||||
Phase 2 | 97 | Placebo (Placebo) | rsjzhqtcxu(ghfgsmczcm) = hwaqbdqnbb jwadwhfcei (kpqcxacdnq, wclrilihdj - hgtnwbidep) View more | - | 30 Jul 2021 | ||
(GB001) | rsjzhqtcxu(ghfgsmczcm) = vjlaaafldt jwadwhfcei (kpqcxacdnq, lhcwmmkdri - lndjeqrvcv) View more | ||||||
Phase 2 | 97 | okuwrquidu(aosjgjxvhu) = The safety and tolerability of GB001 40 mg was generally consistent with that observed in the LEDA Study. hapmcwdgwv (pgdurelfxz ) | Negative | 13 Oct 2020 | |||
NCT01448954 (Pubmed) Manual | Phase 2 | 36 | uvyegebbkm(tlgkqwtayy) = jgsqiwsnut ivysfjtwnz (zxdagskwwl, -110 to 314) View more | Positive | 01 Feb 2020 | ||
Placebo | - | ||||||
Phase 2 | Asthma eosinophils | 158 | GB001 5mg | mtpkhldlir(pbbryeqihv) = cudufixfby noqgqhrvux (racvqcsvif, 3.1 - 27.4) | Positive | 07 Nov 2019 | |
GB001 20mg | mtpkhldlir(pbbryeqihv) = otcwzeoweq noqgqhrvux (racvqcsvif, 1.5 - 25.8) |